Ionis Pharmaceuticals Inc (IONS)
43.20
+0.19
(+0.44%)
USD |
NASDAQ |
May 02, 14:28
Ionis Pharmaceuticals Cash from Financing (TTM): 644.08M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 644.08M |
September 30, 2023 | 552.34M |
June 30, 2023 | 586.44M |
March 31, 2023 | 444.12M |
December 31, 2022 | -55.30M |
September 30, 2022 | -66.77M |
June 30, 2022 | -67.14M |
March 31, 2022 | 246.18M |
December 31, 2021 | 245.93M |
September 30, 2021 | -213.06M |
June 30, 2021 | -203.58M |
March 31, 2021 | -509.68M |
December 31, 2020 | -596.61M |
September 30, 2020 | -55.90M |
June 30, 2020 | -80.02M |
March 31, 2020 | -53.94M |
December 31, 2019 | 100.02M |
September 30, 2019 | 90.44M |
June 30, 2019 | 111.69M |
March 31, 2019 | 530.10M |
December 31, 2018 | 475.86M |
September 30, 2018 | 470.48M |
June 30, 2018 | 609.97M |
March 31, 2018 | 158.76M |
December 31, 2017 | 229.09M |
Date | Value |
---|---|
September 30, 2017 | 231.28M |
June 30, 2017 | 88.25M |
March 31, 2017 | 86.06M |
December 31, 2016 | 11.39M |
September 30, 2016 | 16.66M |
June 30, 2016 | 12.28M |
March 31, 2016 | 14.08M |
December 31, 2015 | 24.73M |
September 30, 2015 | 62.89M |
June 30, 2015 | 64.41M |
March 31, 2015 | 61.80M |
December 31, 2014 | 59.59M |
September 30, 2014 | 13.03M |
June 30, 2014 | 28.71M |
March 31, 2014 | 227.99M |
December 31, 2013 | 227.72M |
September 30, 2013 | 223.25M |
June 30, 2013 | 240.29M |
March 31, 2013 | 50.03M |
December 31, 2012 | 39.13M |
September 30, 2012 | 40.87M |
June 30, 2012 | 5.581M |
March 31, 2012 | -1.797M |
December 31, 2011 | -0.672M |
September 30, 2011 | 1.418M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-596.61M
Minimum
Dec 2020
644.08M
Maximum
Dec 2023
58.91M
Average
-53.94M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | 595.12M |
Viking Therapeutics Inc | 873.23M |
Alnylam Pharmaceuticals Inc | 172.13M |
Akero Therapeutics Inc | 353.32M |
89bio Inc | 513.11M |